-
Je něco špatně v tomto záznamu ?
Exploring the role of nanomedicines for the therapeutic approach of central nervous system dysfunction: At a glance
MM. Rhaman, MR. Islam, S. Akash, M. Mim, M. Noor Alam, E. Nepovimova, M. Valis, K. Kuca, R. Sharma
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články, přehledy
NLK
Directory of Open Access Journals
od 2013
Free Medical Journals
od 2013
PubMed Central
od 2013
Europe PubMed Central
od 2013
Open Access Digital Library
od 2013-01-01
Open Access Digital Library
od 2013-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2013
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
In recent decades, research scientists, molecular biologists, and pharmacologists have placed a strong emphasis on cutting-edge nanostructured materials technologies to increase medicine delivery to the central nervous system (CNS). The application of nanoscience for the treatment of neurodegenerative diseases (NDs) such as Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis (MS), Huntington's disease (HD), brain cancer, and hemorrhage has the potential to transform care. Multiple studies have indicated that nanomaterials can be used to successfully treat CNS disorders in the case of neurodegeneration. Nanomedicine development for the cure of degenerative and inflammatory diseases of the nervous system is critical. Nanoparticles may act as a drug transporter that can precisely target sick brain sub-regions, boosting therapy success. It is important to develop strategies that can penetrate the blood-brain barrier (BBB) and improve the effectiveness of medications. One of the probable tactics is the use of different nanoscale materials. These nano-based pharmaceuticals offer low toxicity, tailored delivery, high stability, and drug loading capacity. They may also increase therapeutic effectiveness. A few examples of the many different kinds and forms of nanomaterials that have been widely employed to treat neurological diseases include quantum dots, dendrimers, metallic nanoparticles, polymeric nanoparticles, carbon nanotubes, liposomes, and micelles. These unique qualities, including sensitivity, selectivity, and ability to traverse the BBB when employed in nano-sized particles, make these nanoparticles useful for imaging studies and treatment of NDs. Multifunctional nanoparticles carrying pharmacological medications serve two purposes: they improve medication distribution while also enabling cell dynamics imaging and pharmacokinetic study. However, because of the potential for wide-ranging clinical implications, safety concerns persist, limiting any potential for translation. The evidence for using nanotechnology to create drug delivery systems that could pass across the BBB and deliver therapeutic chemicals to CNS was examined in this study.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22023378
- 003
- CZ-PrNML
- 005
- 20221031095225.0
- 007
- ta
- 008
- 221010s2022 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3389/fcell.2022.989471 $2 doi
- 035 __
- $a (PubMed)36120565
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Rhaman, Md Mominur $u Department of Pharmacy, Faculty of Allied Health Sciences, Daffodil International University, Dhaka, Bangladesh
- 245 10
- $a Exploring the role of nanomedicines for the therapeutic approach of central nervous system dysfunction: At a glance / $c MM. Rhaman, MR. Islam, S. Akash, M. Mim, M. Noor Alam, E. Nepovimova, M. Valis, K. Kuca, R. Sharma
- 520 9_
- $a In recent decades, research scientists, molecular biologists, and pharmacologists have placed a strong emphasis on cutting-edge nanostructured materials technologies to increase medicine delivery to the central nervous system (CNS). The application of nanoscience for the treatment of neurodegenerative diseases (NDs) such as Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis (MS), Huntington's disease (HD), brain cancer, and hemorrhage has the potential to transform care. Multiple studies have indicated that nanomaterials can be used to successfully treat CNS disorders in the case of neurodegeneration. Nanomedicine development for the cure of degenerative and inflammatory diseases of the nervous system is critical. Nanoparticles may act as a drug transporter that can precisely target sick brain sub-regions, boosting therapy success. It is important to develop strategies that can penetrate the blood-brain barrier (BBB) and improve the effectiveness of medications. One of the probable tactics is the use of different nanoscale materials. These nano-based pharmaceuticals offer low toxicity, tailored delivery, high stability, and drug loading capacity. They may also increase therapeutic effectiveness. A few examples of the many different kinds and forms of nanomaterials that have been widely employed to treat neurological diseases include quantum dots, dendrimers, metallic nanoparticles, polymeric nanoparticles, carbon nanotubes, liposomes, and micelles. These unique qualities, including sensitivity, selectivity, and ability to traverse the BBB when employed in nano-sized particles, make these nanoparticles useful for imaging studies and treatment of NDs. Multifunctional nanoparticles carrying pharmacological medications serve two purposes: they improve medication distribution while also enabling cell dynamics imaging and pharmacokinetic study. However, because of the potential for wide-ranging clinical implications, safety concerns persist, limiting any potential for translation. The evidence for using nanotechnology to create drug delivery systems that could pass across the BBB and deliver therapeutic chemicals to CNS was examined in this study.
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Islam, Md Rezaul $u Department of Pharmacy, Faculty of Allied Health Sciences, Daffodil International University, Dhaka, Bangladesh
- 700 1_
- $a Akash, Shopnil $u Department of Pharmacy, Faculty of Allied Health Sciences, Daffodil International University, Dhaka, Bangladesh
- 700 1_
- $a Mim, Mobasharah $u Department of Pharmacy, Faculty of Allied Health Sciences, Daffodil International University, Dhaka, Bangladesh
- 700 1_
- $a Noor Alam, Md $u Department of Pharmacy, Faculty of Allied Health Sciences, Daffodil International University, Dhaka, Bangladesh
- 700 1_
- $a Nepovimova, Eugenie $u Department of Chemistry, Faculty of Science, University of Hradec Králové, Hradec Králové, Czech Republic
- 700 1_
- $a Valis, Martin $u Department of Neurology, Charles University in Prague, Faculty of Medicine in Hradec Králové and University Hospital, Hradec Králové, Czech Republic
- 700 1_
- $a Kuca, Kamil $u Department of Chemistry, Faculty of Science, University of Hradec Králové, Hradec Králové, Czech Republic $u Andalusian Research Institute in Data Science and Computational Intelligence (DaSCI), University of Granada, Granada, Spain
- 700 1_
- $a Sharma, Rohit $u Department of Rasa Shastra and Bhaishajya Kalpana, Faculty of Ayurveda, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India
- 773 0_
- $w MED00186212 $t Frontiers in cell and developmental biology $x 2296-634X $g Roč. 10, č. - (2022), s. 989471
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36120565 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20221010 $b ABA008
- 991 __
- $a 20221031095223 $b ABA008
- 999 __
- $a ind $b bmc $g 1853838 $s 1174666
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 10 $c - $d 989471 $e 20220902 $i 2296-634X $m Frontiers in cell and developmental biology. $n Front Cell Dev Biol $x MED00186212
- LZP __
- $a Pubmed-20221010